Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. (February 2013)

• Record Type: Journal Article
• Authors: Qiu, Tianzhu; Zhou, Li; Zhu, Wei; Wang, Tongshan; Wang, Jian; Shu, Yongqian; Liu, Ping
• Is Part Of: Future oncology. Volume 9:Number 2(2013)
• Page Start: 255
• Page End: 269
• Publication Date: 2013-02
• Subjects: clinical trial -- histone deacetylase inhibitor -- solid tumor; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.12.173
• Languages: English
• ISSNs: 1479-6694

Abstract

It has been found that the epigenetic silence of tumor suppressor genes induced by overexpression of histone deacetylases (HDACs) plays an important role in carcinogenesis. HDAC inhibitors (HDACi) that block the activity of specific HDACs have emerged as the accessory therapeutic agents for multiple human cancers. To better understand the effects of HDACi in cancer treatment, we carried out a review based on 30 published clinical trials to determine whether HDACi will benefit patients with solid tumors. Information of complete response, partial response, stable disease, objective responses and objective response rate was collected to assess clinical outcomes. A lack of therapeutic effects was observed when HDACi was used as a single agent. However, when HDACi treatment was combined with other agents, it appeared to increase the anti-tumor activity. High-quality studies are required to better understand the clinical effects of HDACi.